微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 53.6% | 7.02% | -11.11% | 68/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 60.3% | 17.19% | 3.99% | 52/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 57.99% | 12.97% | 18.01% | 57/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 49.14% | -12.21% | -1.89% | 80/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 50.09% | -10.44% | -2.66% | 77/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 51.46% | -9.82% | 0.24% | 76/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 51.33% | -6.67% | -8.3% | 74/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 55.98% | -4.36% | 0.09% | 65/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 55.93% | -4.01% | -1.99% | 66/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 57.06% | -4.09% | 3.75% | 63/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 55% | -13.29% | -6.03% | 66/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.53% | -9.01% | 0.46% | 60/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.26% | -10.05% | -2.07% | 61/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 59.5% | -0.14% | -6.2% | 60/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 63.43% | 1.76% | -1.4% | 49/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 64.33% | 32.43% | -0.69% | 55/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.77% | 29.37% | 8.71% | 46/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 59.58% | 28.37% | -4.41% | 58/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 62.33% | 33.47% | 28.32% | 47/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 48.57% | -26.68% | -2.98% | 83/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 50.07% | -25.54% | 7.87% | 68/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 46.42% | -30.35% | -0.61% | 83/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 46.7% | -33.48% | -29.51% | 70/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 66.25% | -8.14% | -1.47% | 42/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 67.24% | -9.53% | 0.9% | 30/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 66.64% | -10.74% | -5.09% | 33/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 70.21% | -4.68% | -2.65% | 22/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 72.12% | -6.65% | -2.97% | 31/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 74.32% | -2.73% | -0.45% | 15/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 74.66% | 1.35% | 1.35% | 15/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 73.66% | 5.26% | -4.66% | 14/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 77.26% | 1.04% | 1.11% | 20/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 76.41% | -1.04% | 3.73% | 11/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 73.66% | -5.13% | 5.26% | 13/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 69.98% | -9.51% | -8.48% | 15/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 76.47% | 3.84% | -0.96% | 13/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 77.21% | 4.43% | -0.56% | 7/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 77.65% | 4.97% | 0.4% | 7/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 77.34% | 7.06% | 5.02% | 5/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 73.64% | 4.25% | -0.4% | 11/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 73.93% | 3.57% | -0.05% | 8/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 73.97% | 4.44% | 2.41% | 9/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 72.23% | 1.78% | 2.26% | 10/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |